Revisions allow you to track differences between multiple versions of your content, and revert back to older versions.

Revisions for A 24-week with possible extension prospective multicentre randomized double blind placebo-controlled 2-parallel group with a randomization 1:1 Phase 3 study to compare efficacy and safety of masitinib at 6 mgkgday to placebo in treatment of...

Primary tabs

RevisionOperations
Sat, 04/04/2020 - 03:20 by Anonymous (not verified)

Update to resource 'Property title'

This is the published revision.
Fri, 03/04/2020 - 20:00 by Anonymous (not verified)

Update to resource 'Property title'

Fri, 03/04/2020 - 03:40 by Anonymous (not verified)

Update to resource 'A 24-week with possible extension prospective multicentre randomized double blind placebo-controlled 2-parallel group with a randomization 1:1 Phase 3 study to compare efficacy and safety of masitinib at 6 mgkgday to placebo in treatment of...'

Sun, 29/03/2020 - 13:19 by Anonymous (not verified)

Update to resource 'A 24-week with possible extension prospective multicentre randomized double blind placebo-controlled 2-parallel group with a randomization 1:1 Phase 3 study to compare efficacy and safety of masitinib at 6 mgkgday to placebo in treatment of...'

Sat, 20/10/2018 - 04:08 by Anonymous (not verified)